Qiagen Shares Surge on Reported Takeover Interest From EQT, Advent
Qiagen stock climbed sharply after reports emerged that private equity firms EQT and Advent International are eyeing a potential takeover of the diagnostics company.
Shares of Qiagen jumped sharply after reports surfaced that two major private equity firms — EQT and Advent International — have expressed interest in acquiring the life-sciences diagnostics company, according to a report from SeekingAlpha. The news sent the stock higher as investors priced in a potential deal premium.
Qiagen, a Netherlands-headquartered molecular diagnostics and sample technology company, has long been considered a strategic asset in the global healthcare tools sector. A successful acquisition by either EQT or Advent would represent a significant private equity push into the life-sciences diagnostics space, which has drawn sustained investor attention following the pandemic-era surge in diagnostic testing demand.
Read more Luxshare Raises $3.1B in Hong Kong's Largest IPO of 2025 →
Both EQT and Advent are experienced healthcare investors with deep pockets and a history of acquiring high-value life-sciences businesses. While no formal offer has been reported, the mere signal of takeover interest from firms of this caliber is typically enough to move share prices meaningfully, as markets anticipate competitive bidding or a negotiated buyout at a premium to current trading levels.
Analysts will be watching closely for any formal announcements or regulatory disclosures that could confirm whether preliminary discussions have advanced. For Qiagen shareholders, the report introduces a fresh catalyst at a time when mergers and acquisitions activity across the healthcare sector has been gradually picking up amid stabilizing interest rates and renewed appetite for large-scale deals.
Continue reading at SeekingAlpha.
